Shares of diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) fell 5.9% in the morning session after the company reported underwhelming fourth-quarter 2024 results as profit margins worsened ...

Exact Sciences Corporation stock surged after Abbott Laboratories announces a $21bn acquisition at $105 per share, driven by Exact's cancer diagnostics leadership. Exact Sciences boasts strong revenue ...

Exact Sciences, Leader in Cancer Screening and Genomics Testing, to Join Abbott Laboratories in 2026 Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test ...

Exact Sciences’ (NDAQ: EXAS) history is a tale of two halves. Founded in 1995 in Marlborough, Massachusetts, “Exact,” as the company is known, went public in 2001 but struggled to find its footing, ...

Exact Sciences is adding early cancer detection to its pipeline through its buyout of Thrive Earlier Detection for up to $2.15 billion in cash and stock. The deal comes just three months after Thrive ...

Exact Sciences earns a BUY rating, driven by innovation in non-invasive cancer detection and the recent launch of Cancerguard. EXAS's core products—Cologuard, Oncotype DX, and OncoDetect—deliver ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Exact Sciences announced on Wednesday that it acquired the rights to a blood-based ...

Google’s EMD algorithm update focused on ridding the SERPs of spammy or low-quality exact match domains. Here's everything you need to know. The EMD, or Exact Match Domain update, was a 2012 Google ...